ZTS Zoetis (ZTS) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001555280
Cluster · 3 insidersCongress · 2
Funds added, last quarter
687
13F, latest reported quarter
Conversions, 180 days
4
Codes C/M, not in net · no price filed
What the filings say about ZTS
Insiders, 180 days
+$886.4K net bought
3 buyers
Congress, 1 year
2 bought · 1 sold
Latest: purchase, 2026-09-18
Zoetis insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Zoetis Inc. insiders bought a net $886.4K of stock across 72 Form 4 purchases and sales, with 3 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 31.0% of the 21,458 shares held after it.
- 2 other insiders bought within 30 days.
- 687 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DAMELIO FRANK A bought about $501.3K of ZTS on May 13, 2026, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 687 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 7.2% of the 27,862 shares held after it.
- 2 other insiders bought within 30 days.
- 687 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Bisaro Paul bought about $151.8K of ZTS on May 13, 2026; 2 other insiders bought within 30 days and 687 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 12.2% of the 24,524 shares held after it.
- 2 other insiders bought within 30 days.
- 687 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director MCCALLISTER MICHAEL B bought about $233.3K of ZTS on May 11, 2026, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 687 funds added in the latest 13F quarter.Context
- 20 earlier Form 4 trades (code P or S) here by this insider (20 sales), the last on Feb 19, 2025.
- The trade is 10.7% of the 101,337 shares held after it.
- No other insider sold within 30 days.
- 687 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer PECK KRISTIN C sold about $1.4M of ZTS on Feb 17, 2026, the largest insider sale at the company since 2024; 687 funds added in the latest 13F quarter.Context
- 20 earlier Form 4 trades (code P or S) here by this insider (20 sales), the last on Feb 19, 2025.
- The trade is 8.2% of the 112,137 shares held after it.
- No other insider sold within 30 days.
- 687 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer PECK KRISTIN C sold about $1.2M of ZTS on Feb 17, 2026, the largest insider sale at the company since 2024; 687 funds added in the latest 13F quarter.72 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$886.4K over 180 days
more than 87% of Pharma & Biotech
Congress
2 members bought in the last year
more than 76% of Pharma & Biotech
Funds
687 funds bought in last quarter
more than 99% of Pharma & Biotech
Revenue
+2.3% year over year
more than 50% of Pharma & Biotech
Margin
28.2% net margin
more than 89% of Pharma & Biotech
Buybacks
$1.2B repurchased, FY to 2026-06-30
more than 93% of Pharma & Biotech
Short interest
4.5% of the float short (float per yahoo 2026-10-26) · 4.1 days to cover · settled 2026-09-30
below 52% of Pharma & Biotech
The situation: each line is one rule over one dataset
3 insiders independently bought a net $886.4K while the stock fell 31% over six months, with no planned sales queued.
What changed in the last 30 days
Oct 28Insider buying stopped: no purchases in 90 days after 3 in the prior 90
Why it matters
The absence is the signal: 3 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.
Oct 12Rep. Gilbert Cisneros sold $1.0K to $15K, disclosed 24 days after the trade
Why it matters
House members report a bracket, not an exact amount, and have 45 days to do it; the trade is weeks old when it becomes public.
Watch ZTS
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-45.5%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ZTS: institutional holders (13F)
13F holdings, latest reported quarter
39,430,181 sh
$2.8B
26,027,984 sh
$1.9B
23,860,445 sh
$1.7B
19,667,723 sh
$1.4B
15,892,903 sh
$1.1B
Congress trades in ZTS
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2026-09-18 · disclosed 24 days later
$1,001 - $15,000
Sold 2026-07-17 · disclosed 49 days later
$1,001 - $15,000
Bought 2026-06-16 · disclosed 16 days later
$1,001 - $15,000
Bought 2026-06-09 · disclosed 36 days later
$1,001 - $15,000
Sold 2026-04-14 · disclosed 24 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ZTS planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
ZTS mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
ProShares Pet Care ETF
$3.1M position · as of 2026-05-31
9.5%
VanEck Agribusiness ETF
$49.0M position · as of 2026-06-30
5.2%
iShares U.S. Pharmaceuticals ETF
$42.4M position · as of 2026-06-30
3.7%
Monarch Dividend Plus Index ETF
$2.1M position · as of 2026-05-31
3.4%
DIAMOND HILL SELECT FUND
$17.1M position · as of 2026-06-30
3.1%
DIAMOND HILL LARGE CAP CONCENTRATED ETF
$2.7M position · as of 2026-06-30
3.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Kristin C. Peck
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$19.0M
$2.8M
$4.0M
-20%
+88%
2024
$17.2M
$759.6K
$3.4M
+2%
+48%
2023
$15.2M
$26.4M
$3.0M
+22%
+37%
2022
$14.0M
-$15.7M
$2.9M
-10%
+36%
2021
$13.1M
$33.5M
$4.5M
+48%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
3 insiders reported buying shares.
The record shows a net $886.4K bought by insiders over 180 days, 687 funds added last quarter, 2 House member(s) bought in 12 months, disclosed weeks after the trade. Each figure is a federal filing, dated the day it went public.
ZTS financials
Revenue growth
+2.3%
XBRL, annual
Net margin
28.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$9.5B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM ZTS
| FY Dec 2025 | $9.5B |
| FY Dec 2024 | $9.3B |
| FY Dec 2023 | $8.5B |
| FY Dec 2022 | $8.1B |
| FY Dec 2021 | $7.8B |
| Jun 2026 | $2.5B |
| Mar 2026 | $2.3B |
| Dec 2025 | $2.4B |
| Sep 2025 | $2.4B |
| Jun 2025 | $2.5B |
| Mar 2025 | $2.2B |
| Dec 2024 | $2.3B |
| Sep 2024 | $2.4B |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Net margin, TTM ZTS
| FY Dec 2025 | n/a |
| FY Dec 2024 | +26.9% |
| FY Dec 2023 | +27.4% |
| FY Dec 2022 | +26.2% |
| FY Dec 2021 | +26.2% |
| Jun 2026 | +28.0% |
| Mar 2026 | +26.6% |
| Dec 2025 | +25.3% |
| Sep 2025 | +30.0% |
| Jun 2025 | +29.3% |
| Mar 2025 | +27.1% |
| Dec 2024 | +25.1% |
| Sep 2024 | +28.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$2.3B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ZTS
| FY Dec 2025 | $2.3B |
| FY Dec 2024 | $2.3B |
| FY Dec 2023 | $1.6B |
| FY Dec 2022 | $1.3B |
| FY Dec 2021 | $1.7B |
| Jun 2026 | $538.0M |
| Mar 2026 | $291.0M |
| Dec 2025 | $732.0M |
| Sep 2025 | $755.0M |
| Jun 2025 | $459.0M |
| Mar 2025 | $337.0M |
| Dec 2024 | $689.0M |
| Sep 2024 | $784.0M |
At each fiscal year end
Single quarter
Debt to equity
2.87x
long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end); equity 2026-06-30
Debt to equity ZTS
| FY Dec 2025 | 2.65x |
| FY Dec 2024 | 1.38x |
| FY Dec 2023 | 1.31x |
| FY Dec 2022 | 1.79x |
| FY Dec 2021 | 1.45x |
| Jun 2026 | 2.87x |
| Mar 2026 | 2.80x |
| Dec 2025 | 2.65x |
| Sep 2025 | 1.31x |
| Jun 2025 | 1.32x |
| Mar 2025 | 1.41x |
| Dec 2024 | 1.38x |
| Sep 2024 | 1.26x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.31x
TTM operating cash flow over long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end)
Cash flow to debt ZTS
| FY Dec 2025 | 0.32x |
| FY Dec 2024 | 0.45x |
| FY Dec 2023 | 0.36x |
| FY Dec 2022 | 0.24x |
| FY Dec 2021 | 0.34x |
| Jun 2026 | 0.31x |
| Mar 2026 | 0.31x |
| Dec 2025 | 0.32x |
| Sep 2025 | 0.41x |
| Jun 2025 | 0.45x |
| Mar 2025 | 0.44x |
| Dec 2024 | 0.45x |
| Sep 2024 | 0.45x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on equity ZTS
| FY Dec 2025 | n/a |
| FY Dec 2024 | +50.9% |
| FY Dec 2023 | +49.9% |
| FY Dec 2022 | +47.3% |
| FY Dec 2021 | +49.0% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | +49.5% |
| Jun 2025 | +52.1% |
| Mar 2025 | +51.3% |
| Dec 2024 | +50.9% |
| Sep 2024 | +47.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on assets ZTS
| FY Dec 2025 | n/a |
| FY Dec 2024 | +17.4% |
| FY Dec 2023 | +16.0% |
| FY Dec 2022 | +14.7% |
| FY Dec 2021 | +14.8% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | +17.8% |
| Jun 2025 | +18.1% |
| Mar 2025 | +17.5% |
| Dec 2024 | +17.4% |
| Sep 2024 | +17.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital ZTS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed ZTS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
12.89x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing ZTS
| FY Dec 2025 | 21.08x |
| FY Dec 2024 | 29.79x |
| FY Dec 2023 | 38.93x |
| FY Dec 2022 | 32.64x |
| FY Dec 2021 | 57.15x |
| Jun 2026 | 11.84x |
| Mar 2026 | 19.54x |
| Dec 2025 | 21.08x |
| Sep 2025 | 24.84x |
| Jun 2025 | 27.07x |
| Mar 2025 | 29.94x |
| Dec 2024 | 29.79x |
| Sep 2024 | 36.73x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$39.9B
market value at close 2026-10-27 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end), minus cash 2026-06-30
Enterprise value ZTS
| FY Dec 2025 | $62.0B |
| FY Dec 2024 | $78.1B |
| FY Dec 2023 | $95.1B |
| FY Dec 2022 | $72.6B |
| FY Dec 2021 | $118.6B |
| Jun 2026 | $37.7B |
| Mar 2026 | $57.0B |
| Dec 2025 | $62.0B |
| Sep 2025 | $69.8B |
| Jun 2025 | $74.6B |
| Mar 2025 | $78.6B |
| Dec 2024 | $78.1B |
| Sep 2024 | $93.4B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+7.2%
TTM free cash flow over market value at close 2026-10-27
FCF yield ZTS
| FY Dec 2025 | +4.1% |
| FY Dec 2024 | +3.1% |
| FY Dec 2023 | +1.8% |
| FY Dec 2022 | +1.9% |
| FY Dec 2021 | +1.5% |
| Jun 2026 | +7.7% |
| Mar 2026 | +4.5% |
| Dec 2025 | +4.1% |
| Sep 2025 | +3.5% |
| Jun 2025 | +3.3% |
| Mar 2025 | +3.0% |
| Dec 2024 | +3.1% |
| Sep 2024 | +2.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
2.39x
P/E over trailing EPS growth of 5%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing ZTS
| FY Dec 2025 | 2.31x |
| FY Dec 2024 | 3.78x |
| FY Dec 2023 | 3.01x |
| FY Dec 2022 | 6.33x |
| FY Dec 2021 | 2.30x |
| Jun 2026 | 2.20x |
| Mar 2026 | 1.95x |
| Dec 2025 | 2.31x |
| Sep 2025 | 2.32x |
| Jun 2025 | 2.13x |
| Mar 2025 | 5.01x |
| Dec 2024 | 3.78x |
| Sep 2024 | 4.40x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $9.5B | $9.3B | $8.5B | $8.1B |
| Net income | $2.7B | $2.5B | $2.3B | $2.1B |
| EPS (diluted) | 6.02 | 5.47 | 5.07 | 4.49 |
| Operating cash flow | $2.9B | $3.0B | $2.4B | $1.9B |
| Cash | $2.5B | $2.0B | $2.0B | $3.6B |
| Long-term debt | $9.0B | $5.2B | $6.6B | $6.6B |
| Buybacks | $3.2B | $1.9B | $1.1B | $1.6B |
SEC XBRL, fiscal years, as known on 2026-10-28
ZTS Stock Sonar score 5/7 axes
Find similar shapesCompareZTS ranks highest on insider conviction (88th percentile) and institutional and government (79th), and lowest on risk and compliance (37th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ZTS filings, in plain words
Are Zoetis insiders buying or selling ZTS?
In the 180 days to 2026-10-28, Zoetis insiders were net buyers, a net $886.4K across purchases and sales reported on Form 4, by 3 buyers.
Have members of Congress traded ZTS?
Yes. In the year to 2026-10-28, 2 House members disclosed buying ZTS and 1 House member disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-09-18.
Read the full summary
In the 180 days to 2026-10-28, Zoetis insiders were net buyers of ZTS, a net $886.4K across purchases and sales reported on Form 4 by 3 buyers. 3 insiders reported purchases in that window. In the year to 2026-10-28, 2 members of Congress disclosed buying ZTS and 1 member disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-09-18. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
